Yongtai Bio-B (06978) disclosed the 2023 annual results announcement. The company achieved about 1 other revenue during the reporting period...
According to the Zhitong Finance App, Yongtai Bio-B (06978) disclosed the 2023 annual results announcement. The company achieved other revenue of about 10.5 million yuan (RMB, same below) during the reporting period, an increase of about 15.4% over the previous year. The R&D expenditure was approximately 177 million yuan.
It is reported that the company plans to conduct an EALExpanding clinical research on indications. Multiple clinical studies have shown that EALIt is effective in treating various tumors other than liver cancer. at EALAfter the indications for liver cancer are approved for marketing, the company plans to expand its clinical indications to diseases such as lung cancer, gastric cancer, glioma, and colorectal cancer. The company is currently working on a project to EALPreclinical study for gastric cancer as an indication. Pharmacodynamics studies have been completed, and pharmacological and toxicological studies are ongoing. The company expects to be in EALAfter completing the approval of liver cancer indications, submit a clinical research application to the Drug Evaluation Center.
Additionally, the company plans to continue investing in the CAR-T and TCR-T cell product lines. In particular, in March 2023, the company obtained clinical approval from the National Drug Administration for dinolense injections. In February 2024, the company obtained clinical approval from the State Drug Administration for aT19 injections.
On the basis of endogenous growth, the company plans to expand strategic cooperation, explore merger and acquisition opportunities, and seek sales, technology transfer and strategic cooperation for existing products and R&D products. The company will also continue to seek new potential development directions for cellular immunotherapy products and explore opportunities for mergers and acquisitions and strategic cooperation.